Investors
NEWS & UPDATES
Press Releases
September 15, 2026
Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in the treatment of KRAS-Mutant Advanced Solid Tumors
Kestrel Therapeutics Announces FDA Fast Track Designation for KST-6051, a oral pan-KRAS inhibitor, for the treatment of patients with advanced or metastatic solid tumors harboring KRAS mutations.
Read MoreApril 28, 2026
Kestrel Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
Kestrel Therapeutics announced the first patient has been dosed in its Phase 1 clinical trial evaluating KST-6051 in patients with KRAS-driven cancers.
Read MoreMarch 5, 2026
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trials
Kestrel is advancing KST-6051 into the clinic and expects to initiate a first-in-human Phase 1 dose escalation clinical trial FALCON by the end of the first quarter.
Read MoreKestrel Therapeutics has attracted funding from thought-leading investors.
Investor Inquiries
For investor inquiries, please contact Sandya von der Weid at [email protected]